Drugs / CV09070101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07073183 | Jul 2025 → Dec 2029 | non-small cell squamous lung carcinoma | CureVac | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-07 | CureVac | Regulatory CureVac erhält IND-Freigabe der U.S.-amerikanischen FDA für den Start einer klinischen Phase 1-Studie mit einer neuartigen mRNA-Präzisions-Immuntherapie beim Plattenepithelkarzinom der Lunge curevac.com ↗
gab heute bekannt, dass die U.S. Food and Drug Administration (FDA) ihren IND-Antrag (Investigational New Drug) für eine klinische Phase 1-Studie mit CVHNLC bei Patienten mit nicht-kleinzelligem Plattenepithelkarzinom der Lunge (sqNSCLC) freigegeben hat. |
All press releases naming this drug 1 release
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CV09070101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07073183 ↗ |
| Known as | CVHNLC | “CV09070101 mRNA vaccine (CVHNLC) 50 µg” NCT07073183 ↗ |
| Modality | Messenger RNA (mRNA) | “CV09070101 mRNA vaccine (CVHNLC) 50 µg” NCT07073183 ↗ |
| Route | Intramuscular | “CVHNLC will be administered as in IM injection” NCT07073183 ↗ |